Rowan University

Rowan Digital Works
Stratford Campus Research Day

26th Annual Research Day

May 5th, 12:00 AM

Assessing the Effectiveness of Phone Call Proactive Naloxone
Co-Prescribing Enrollment
Tyler Klecha
Rowan University

David Aloisio
Rowan University

Eshani Choksi
Rowan University

Manasa Gowda
Rowan University

Christina Kanagawa
Rowan University

See next page for additional authors
Follow this and additional works at: https://rdw.rowan.edu/stratford_research_day
Part of the Community Health and Preventive Medicine Commons, Medicine and Health Commons,
Public Health Education and Promotion Commons, and the Substance Abuse and Addiction Commons

Let us know how access to this document benefits you - share your thoughts on our feedback
form.
Klecha, Tyler; Aloisio, David; Choksi, Eshani; Gowda, Manasa; Kanagawa, Christina; and Defendorf, Charles
M., "Assessing the Effectiveness of Phone Call Proactive Naloxone Co-Prescribing Enrollment" (2022).
Stratford Campus Research Day. 19.
https://rdw.rowan.edu/stratford_research_day/2022/May5/19

This Poster is brought to you for free and open access by the Conferences, Events, and Symposia at Rowan Digital
Works. It has been accepted for inclusion in Stratford Campus Research Day by an authorized administrator of
Rowan Digital Works.

Author(s)
Tyler Klecha, David Aloisio, Eshani Choksi, Manasa Gowda, Christina Kanagawa, and Charles M.
Defendorf

This poster is available at Rowan Digital Works: https://rdw.rowan.edu/stratford_research_day/2022/May5/19

Assessing the Effectiveness of Phone Call Proactive Naloxone
Co-Prescribing Enrollment
Tyler Klecha, OMS-II; David Aloisio, OMS-II; Eshani Choksi, OMS-II; Manasa Gowda, OMS-II; Christina
Kanagawa, OMS-II; Charles M. Defendorf, DO
RowanSOM Department of Internal Medicine
42 E. Laurel Road, Suite 1800, Stratford, NJ 08084

Abstract
Opioid use is increasing at never-before-seen
rates. As a result, it is imperative that medical
facilities educate and provide resources for those
who may be at risk of an opioid overdose. With
our study, we aimed to see the demographics of
our population here at Rowan Medicine and
identify associations of those participating in our
naloxone co-prescription program. Majority of
enrollees in our program were aged 50 or older
and identified as Caucasian. A large proportion
also reported being unable to work. Given this
information, improvements in our naloxone coprescription program may include spreading
more awareness of the benefits of naloxone to
minority populations, as well as to the younger
population at risk of an opioid overdose.

Methods

Conclusions

Participants involved in this study were recruited by the principal investigator through a retrospective chart
review. Individuals who were identified as one who would benefit from having a naloxone prescription
through various criteria were initially contacted by phone, and upon verification of their eligibility, were
asked to complete a Qualtrics survey sent via email. Twelve questions asked in the survey, were regarding
the population’s demographics. Answers to these questions were then compiled, and results were run
through the statistical analyses program IBM SPSS. Pearson correlation tests were utilized when indicated.

Fig. 1-6: Responses to Survey Questions Regarding Participants’ Demographics
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Introduction

Opioids are a class of medications that have
garnered mass attention in media in recent
years, with approximately 3-4% of the U.S. adult
population having been prescribed a long-term
opioid therapy for their chronic pain.1 However,
opioid use presents with a plethora of serious
risks, with more than 165,000 people having died
of an opioid overdose from 1999 to 2014.2,3
Opioid misuse and overdoses have continued to
increase over time, and as a result, the United
States Food and Drug administration has
released recommendations in July of 2020 for
health care professionals to discuss naloxone coprescription with all patients who are at an
increased risk of an opioid overdose.4,5 With such
recommendations, our research aimed to look at
the effectiveness of a phone call naloxone coprescribing program with all patients who are at
an increased risk of an opioid overdose,
particularly studying the demographics of
participants involved within such a program at
Rowan Medicine. It has been shown that
community efforts to increase access to naloxone
are cost-effective and reduce mortality
associated with opioid overdoses; however, there
is limited data regarding targeted naloxone
distribution and effectiveness of individual
naloxone co-prescription programs.
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Majority of the participants in our study identified
as Caucasian and were over the age of 50. As a
result, there is possible correlation between
ethnicity and risk of opioid use/overdose,
specifically a higher risk in the Caucasian
population. Age may also be a potential factor in
one’s risk of opioid use, thereby increasing the
chance that participants in a naloxone coprescription program are a certain age or older.
Older patients are more likely to be using opioid
medications for treatment of pain and other health
issues, thereby increasing the chance that an
older patient will be in a naloxone co-prescription
program, as opposed to a younger individual who
is not taking as many medications. There was
also another trend which was seen regarding work
status. A large proportion of those enrolled within
this program, almost half, reported that they were
unable to work. While we did not ask reasons as
to why one may not be able to work, one’s
unemployment may be related to use of opioids
and risk. Further studies are required to identify
stronger trends and associations. A study
involving a larger and more diverse population
would help to see where improvement efforts can
be guided, such as increasing naloxone
awareness within populations or identifying who is
more at risk of an adverse opioid use event.
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